What is the level of liabilities of Supernus Pharmaceuticals this year?
Supernus Pharmaceuticals has a debt balance of 356.16 M USD this year.
In 2024, Supernus Pharmaceuticals's total liabilities amounted to 356.16 M USD, a -56.37% difference from the 816.3 M USD total liabilities in the previous year.
Supernus Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Supernus Pharmaceuticals's financial stability, operational efficiency, and long-term viability.
By comparing Supernus Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Supernus Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Shifts in Supernus Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Supernus Pharmaceuticals has a debt balance of 356.16 M USD this year.
The liabilities of Supernus Pharmaceuticals have increased by -56.37% dropped compared to the previous year.
High liabilities can pose a risk for investors of Supernus Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.
Low liabilities mean that Supernus Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.
An increase in liabilities of Supernus Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
A decrease in the liabilities of Supernus Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
Some factors that can influence the liabilities of Supernus Pharmaceuticals include investments, acquisitions, operating costs, and sales development.
The liabilities of Supernus Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
To change its liabilities, Supernus Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.
The current dividend yield of Supernus Pharmaceuticals is .
Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
Supernus Pharmaceuticals paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Supernus Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of Supernus Pharmaceuticals from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.
The last dividend was paid out on 8/24/2024.
In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.
The dividends of Supernus Pharmaceuticals are distributed in USD.
Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.